Market Overview

UPDATE: Canaccord Genuity Reiterates Buy Rating, Lowers PT on Amarin Corporation

Share:
Related AMRN
Benzinga's Top #PreMarket Losers
Amarin, LeapFrog Lead Monday's After-Hours Movers

In a report published Friday, Canaccord Genuity reiterated its Buy rating on Amarin Corporation (NASDAQ: AMRN), but lowered its price target from $26.00 to $19.00.

Canaccord Genuity noted, “Reiterate BUY, lowering target to $19; maintain positive view on Vascepa commercial, partnering potential while acknowledging increased commercial risk. We continue to expect business development talks to intensify and Vascepa to receive NCE (five-year exclusivity). Our $19 target is based on a sum-of-the-parts analysis, combining a DCF of high triglyceride sales and pNPV of mixed dyslipidemia sales.”

Amarin Corporation closed on Thursday at $11.95.

Latest Ratings for AMRN

DateFirmActionFromTo
Mar 2015HC WainwrightUpgradesBuy
Feb 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
Nov 2014CitigroupMaintainsNeutral

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (AMRN)

Around the Web, We're Loving...